Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer's disease patients

Imagem de Miniatura
Arquivos
art_COSTA_Donepezil_effects_on_cholesterol_and_oxysterol_plasma_levels_2018.PDF (603.78 KB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER HEIDELBERG
Autores
Citação
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, v.268, n.5, p.501-507, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cholesterol is an essential component in the structure and function of cell membranes and has been associated with the major pathological signatures of Alzheimer's disease (AD). To maintain brain cholesterol homeostasis, it is converted into 24(S)-hydroxycholesterol (24OHC) which can be driven through the blood-brain barrier. Several studies have already described a decrease in 24OHC and an increase of 27(S)-hydroxycholesterol (27OHC) in AD, as a reflection of disease burden, the loss of metabolically active neurons and the degree of structural atrophy. It is also well known that peripheral cholesterol is altered in AD patients. However, there are no data regarding effects of AD treatment in this cholesterol pathway. Since a study from our group indicated a significant increase in membrane phospholipid metabolism by donepezil, the aim of this study was to evaluate the effect of short- and long-term donepezil treatment on cholesterol and metabolites 24OHC and 27OHC in plasma of AD patients and in healthy volunteers. At baseline, we found a decrease of 24OHC (p = 0.003) in AD patients. Cholesterol levels increased with donepezil treatment (p = 0.04) but no differences were observed regarding 24OHC and 27OHC. However, these results confirm and extend previous studies demonstrating disturbed cholesterol turnover in Alzheimer's disease.
Palavras-chave
Oxysterols, 24(S)-Hydroxycholesterol, 27(S)-Hydroxycholesterol, Cholesterol, Alzheimer's disease, Donepezil
URI
https://observatorio.fm.usp.br/handle/OPI/28239
Referências
  1. Abildayeva K, 2006, J BIOL CHEM, V281, P12799, DOI 10.1074/jbc.M601019200
  2. Adibhatla RM, 2006, AAPS J, V8, pE314
  3. Adibhatla Rao Muralikrishna, 2008, V49, P241, DOI 10.1007/978-1-4020-8831-5_9
  4. Adunsky A, 2004, ARCH GERONTOL GERIAT, V38, P61, DOI [10.1016/j.archger.2003.08.002, 10.1016/j.archer.2003.08.002]
  5. Babiker A, 1998, BBA-LIPID LIPID MET, V1392, P333, DOI 10.1016/S0005-2760(98)00047-2
  6. Besga A, 2012, NEUROSCI LETT, V510, P121, DOI 10.1016/j.neulet.2012.01.017
  7. Bjorkhem I, 1998, J LIPID RES, V39, P1594
  8. Bjorkhem I, 2010, J LIPID RES, V51, P2489, DOI 10.1194/jlr.R006338
  9. Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7
  10. Bretillon L, 2000, NEUROSCI LETT, V293, P87, DOI 10.1016/S0304-3940(00)01466-X
  11. Bretillon L, 2000, J LIPID RES, V41, P840
  12. Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620
  13. Burkard I, 2007, ATHEROSCLEROSIS, V194, P71, DOI 10.1016/j.atherosclerosis.2006.09.026
  14. Cacabelos Ramon, 2007, Neuropsychiatr Dis Treat, V3, P303
  15. Cheng HP, 2007, NAT CLIN PRACT NEURO, V3, P374, DOI 10.1038/ncpneuro0549
  16. Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
  17. de Chaves EP, 2008, FUTURE LIPIDOL, V3, P505, DOI 10.2217/17460875.3.5.505
  18. Dzeletovic S, 1995, ANAL BIOCHEM, V22, P573
  19. Famer D, 2007, BIOCHEM BIOPH RES CO, V359, P46, DOI 10.1016/j.bbrc.2007.05.033
  20. FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
  21. Forlenza OV, 2010, REV BRAS PSIQUIATR, V32, P216, DOI 10.1590/S1516-44462010005000002
  22. Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014
  23. Gattaz WF, 1996, FORTSCHR NEUROL PSYC, V64, P8, DOI 10.1055/s-2007-996367
  24. Gosselet F, 2014, BIOCHEM BIOPH RES CO, V446, P687, DOI 10.1016/j.bbrc.2013.11.059
  25. Heverin M, 2004, J LIPID RES, V45, P186, DOI 10.1194/jlr.M300320-JLR200
  26. Hong C, 2014, NAT REV DRUG DISCOV, V13, P433, DOI 10.1038/nrd4280
  27. Iuliano L, 2010, J ALZHEIMERS DIS, V21, P1383, DOI 10.3233/JAD-2010-100780
  28. Karrenbauer VD, 2006, CLIN NEUROL NEUROSUR, V108, P456, DOI 10.1016/j.clineuro.2005.07.010
  29. Kolsch H, 2004, NEUROSCI LETT, V368, P303, DOI 10.1016/j.neulet.2004.07.031
  30. Koudinov AR, 2001, FASEB J, V15, P1858, DOI 10.1096/fj.00-0815fje
  31. LAITINEN J, 1994, BIOTECHNIQUES, V17, P316
  32. Leoni V, 2011, NEUROSCI LETT, V494, P245, DOI 10.1016/j.neulet.2011.03.025
  33. Leoni V, 2013, BIOCHIMIE, V95, P595, DOI 10.1016/j.biochi.2012.09.025
  34. Leoni V, 2011, CHEM PHYS LIPIDS, V164, P515, DOI 10.1016/j.chemphyslip.2011.04.002
  35. Leyhe T, 2009, INT J NEUROPSYCHOPH, V12, P1319, DOI 10.1017/S1461145709990216
  36. Lim WLF, 2014, J GENET GENOMICS, V41, P261, DOI 10.1016/j.jgg.2014.04.003
  37. Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238
  38. Lutjohann D, 2000, J LIPID RES, V41, P195
  39. Mahley RW, 2016, ARTERIOSCL THROM VAS, V36, P1305, DOI 10.1161/ATVBAHA.116.307023
  40. Martins IJ, 2009, J NEUROCHEM, V111, P1275, DOI 10.1111/j.1471-4159.2009.06408.x
  41. Marwarha G, 2010, J NEUROCHEM, V115, P373, DOI 10.1111/j.1471-4159.2010.06929.x
  42. Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399
  43. MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
  44. Garcia ANM, 2009, J MOL NEUROSCI, V39, P342, DOI 10.1007/s12031-009-9227-2
  45. Noh MY, 2013, J NEUROCHEM, V127, P562, DOI 10.1111/jnc.12319
  46. Papassotiropoulos A, 2000, NEUROREPORT, V11, P1959, DOI 10.1097/00001756-200006260-00030
  47. Pappolla MA, 2003, NEUROLOGY, V61, P199, DOI 10.1212/01.WNL.0000070182.02537.84
  48. Popp J, 2013, BIOCHEM PHARMACOL, V86, P37, DOI 10.1016/j.bcp.2012.12.007
  49. Popp J, 2012, J NEUROCHEM, V123, P310, DOI 10.1111/j.1471-4159.2012.07893.x
  50. Prasanthi JRP, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-1
  51. Prasanthi JR, 2011, PLOS ONE, V6, P2640
  52. Qureischie H, 2008, BRAIN RES, V1232, P1, DOI 10.1016/j.brainres.2008.07.047
  53. ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698
  54. Schaeffer EL, 2009, PSYCHOPHARMACOLOGY, V202, P37, DOI 10.1007/s00213-008-1351-0
  55. Seo Y, 2014, J NEUROPATH EXP NEUR, V73, P234, DOI 10.1097/NEN.0000000000000045
  56. Shen H, 2010, BRIT J PHARMACOL, V161, P127, DOI 10.1111/j.1476-5381.2010.00894.x
  57. Solfrizzi V, 2002, J NEUROL NEUROSUR PS, V72, P732, DOI 10.1136/jnnp.72.6.732
  58. Solomon A, 2009, DEMENT GERIATR COGN, V28, P75, DOI 10.1159/000231980
  59. Solomon A, 2009, NEUROSCI LETT, V462, P89, DOI 10.1016/j.neulet.2009.06.073
  60. Talib LL, 2015, EUR ARCH PSY CLIN N, V265, P701, DOI 10.1007/s00406-015-0600-6
  61. Tedde A, 2006, NEUROBIOL AGING, V5
  62. Teunissen CE, 2003, NEUROBIOL AGING, V24, P893, DOI 10.1016/S0197-4580(03)00005-8
  63. Vance JE, 2005, SEMIN CELL DEV BIOL, V16, P193, DOI 10.1016/j.semcdb.2005.01.005
  64. Vance JE, 2012, DIS MODEL MECH, V5, P746, DOI 10.1242/dmm.010124
  65. Wood WG, 2014, J NEUROCHEM, V129, P559, DOI 10.1111/jnc.12637
  66. Yamanaka K, 2011, J BIOL CHEM, V286, P24666, DOI 10.1074/jbc.M111.236273
  67. Zuliani G, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-121

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/10
Artigos e Materiais de Revistas Científicas - LIM/27